Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy

키워드

참고문헌 (49)

1. Xavier RJ, "Unravelling the pathogenesis of inflammatory bowel disease", Nature, 448, pp.427~434 (2007)
2. Travis SP, "European evidence based consensus on the diagnosis and management of Crohn’s disease: current management", Gut, 55(1), pp.i16~i35 (2006)
3. Lémann M, "Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial", Gastroenterology, 130, pp.1054~1061 (2006)
4. Mayer L, "Evolving paradigms in the pathogenesis of IBD", J Gastroenterol, 45, pp.9~16 (2010)
5. Mizoguchi A, "Inflammatory bowel disease, past, present and future: lessons from animal models", J Gastroenterol, 43, pp.1~17 (2008)
6. Papadakis KA, "Role of cytokines in the pathogenesis of inflammatory bowel disease", Annu Rev Med, 51, pp.289~298 (2000)
7. Fiocchi C, "Inflammatory bowel disease: etiology and pathogenesis", Gastroenterology, 115, pp.182~205 (1998)
8. Monney L, "Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease", Nature, 415, pp.536~541 (2002)
9. Anderson AC, "TIM-3 in autoimmunity", Curr Opin Immunol, 18, pp.665~669 (2006)
10. Sánchez-Fueyo A, "Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance", Nat Immunol, 4, pp.1093~1101 (2003)
11. Chen Y, "Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis", J Clin Invest, 116, pp.1317~1326 (2006)
12. Nakae S, "Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17", J Leukoc Biol, 81, pp.1258~1268 (2007)
13. Zhu C, "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity", Nat Immunol, 6, pp.1245~1252 (2005)
14. Li X, "Involvement of T cell Ig Mucin-3 (Tim-3) in the negative regulation of inflammatory bowel disease", Clin Immunol, 134, pp.169~177 (2010)
15. Nadkarni S, "Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta", J Exp Med, 204, pp.33~39 (2007)
16. Izcue A, "Special regulatory T-cell review: regulatory T cells and the intestinal tract--patrolling the frontier", Immunology, 123, pp.6~10 (2008)
17. Holländer GA, "Severe colitis in mice with aberrant thymic selection", Immunity, 3, pp.27~38 (1995)
18. Mottet C, "Cutting edge: cure of colitis by CD4+CD25+ regulatory T cells", J Immunol, 170, pp.3939~3943 (2003)
19. Hori S, "Control of regulatory T cell development by the transcription factor Foxp3", Science, 299, pp.1057~1061 (2003)
20. Fontenot JD, "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells", Nat Immunol, 4, pp.330~336 (2003)
21. Wehkamp J, "Defensins and other antimicrobial peptides in inflammatory bowel disease", Curr Opin Gastroenterol, 23, pp.370~378 (2007)
22. Dhaliwal W, "Intestinal defensin gene expression in human populations", Mol Immunol, 40, pp.469~475 (2003)
23. Lehrer RI, "Primate defensins", Nat Rev Microbiol, 2, pp.727~738 (2004)
24. Siegmund B, "Innate and adaptive immunity in inflammatory bowel disease", World J Gastroenterol, 17, pp.3178~3183 (2011)
25. Uhlig HH, "Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology", Immunity, 25, pp.309~318 (2006)
26. Hue S, "Interleukin-23 drives innate and T cell-mediated intestinal inflammation", J Exp Med, 203, pp.2473~2483 (2006)
27. Becker C, "Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis", J Immunol, 177, pp.2760~2764 (2006)
28. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition, "Inflammatory bowel disease in children and adolescents: recommendations for diagnosis--the Porto criteria", J Pediatr Gastroenterol Nutr, 41, pp.1~7 (2005)
29. Hyams JS, "Development and validation of a pediatric Crohn’s disease activity index", J Pediatr Gastroenterol Nutr, 12, pp.439~447 (1991)
30. Allen JE, "Th1-Th2: reliable paradigm or dangerous dogma?", Immunol Today, 18, pp.387~392 (1997)
31. Rook G, "Th1- or Th2-cell commitment during infectious disease: an oversimplification?", Trends Immunol, 22, pp.481~482 (2001)
32. Anderson DE, "TIM-3 as a therapeutic target in human inflammatory diseases", Expert Opin Ther Targets, 11, pp.1005~1009 (2007)
33. Morimoto K, "Dysregulated upregulation of T-cell immunoglobulin and mucin domain-3 on mucosal T helper 1 cells in patients with Crohn’s disease", Scand J Gastroenterol, 46, pp.701~709 (2011)
34. Nakae S, "TIM-1 and TIM-3 enhancement of Th2 cytokine production by mast cells", Blood, 110, pp.2565~2568 (2007)
35. Cua DJ, "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", Nature, 421, pp.744~748 (2003)
36. Anderson AC, "Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells", Science, 318, pp.1141~1143 (2007)
37. Wang F, "The Tim-3 ligand galectin-9 negatively regulates CD8+ alloreactive T cell and prolongs survival of skin graft", Cell Immunol, 250, pp.68~74 (2007)
38. Sarin A, "Cytotoxic effect of TNF and lymphotoxin on T lymphoblasts", J Immunol, 155, pp.3716~3718 (1995)
39. Kelsen J, "FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn’s disease", Clin Exp Immunol, 141, pp.549~557 (2005)
40. Zelenay S, "Foxp3+ CD25- CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion", Proc Natl Acad Sci U S A, 102, pp.4091~4096 (2005)
41. Saruta M, "Characterization of FOXP3+CD4+ regulatory T cells in Crohn’s disease", Clin Immunol, 125, pp.281~290 (2007)
42. Makita S, "CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells", J Immunol, 173, pp.3119~3130 (2004)
43. Muratov V, "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis", J Gastroenterol, 43, pp.277~282 (2008)
44. Li Z, "Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab", Inflamm Bowel Dis, 16, pp.1299~1310 (2010)
45. Maul J, "Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease", Gastroenterology, 128, pp.1868~1878 (2005)
46. La Scaleia R, "Peripheral and intestinal CD4+ T cells with a regulatory phenotype in pediatric patients with inflammatory bowel disease", J Pediatr Gastroenterol Nutr, 51, pp.563~572 (2010)
47. Doss M, "Human defensins and LL-37 in mucosal immunity", J Leukoc Biol, 87, pp.79~92 (2010)
48. Bowdish DM, "Immunomodulatory properties of defensins and cathelicidins", Curr Top Microbiol Immunol, 306, pp.27~66 (2006)
49. O’Neil DA, "Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium", J Immunol, 163, pp.6718~6724 (1999)

관련 논문AI추천